CRISPR Therapeutics AG — Director's Dealing 2020

Dec 22, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2020-12-21

Reporting Person: Ho Tony W (Executive VP, Head of R&D)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-21	Common Shares	M	23551	$16.90	Acquired	57515	Direct
2020-12-21	Common Shares	S	1700	$148.11	Disposed	55815	Direct
2020-12-21	Common Shares	S	900	$149.18	Disposed	54915	Direct
2020-12-21	Common Shares	S	1600	$150.16	Disposed	53315	Direct
2020-12-21	Common Shares	S	1100	$151.58	Disposed	52215	Direct
2020-12-21	Common Shares	S	500	$152.41	Disposed	51715	Direct
2020-12-21	Common Shares	S	1400	$147.05	Disposed	50315	Direct
2020-12-21	Common Shares	S	8400	$148.38	Disposed	41915	Direct
2020-12-21	Common Shares	S	5000	$149.73	Disposed	36915	Direct
2020-12-21	Common Shares	S	2951	$150.61	Disposed	33964	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-21	Stock Option (right to buy)	$16.90	M	23551	Disposed	2027-08-01	Common Shares (23551)	Direct

Footnotes

F1: Includes 217 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.44 to $148.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.69 to $149.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.755 to $150.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.00 to $151.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.04 to $152.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.00 to $147.125, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.19 to $149.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.20 to $150.195, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.44 to $151.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F12: This option was granted on August 1, 2017 with respect to 260,000 Common Shares of which 25% vested on 8/1/2018 and the remaining 75% vest in 36 equal monthly installments on the final day of each succeeding calendar month.